Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results
View ORCID ProfileRu Han, Clément François, Mondher Toumi
doi: https://doi.org/10.1101/2020.06.22.20135434
Ru Han
1University of Aix-Marseille, Marseille, France
2Creativ-Ceutical, Paris, France
Clément François
1University of Aix-Marseille, Marseille, France
2Creativ-Ceutical, Paris, France
Mondher Toumi
1University of Aix-Marseille, Marseille, France
2Creativ-Ceutical, Paris, France
Posted June 23, 2020.
Systematic review of health state utility values used in pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results
Ru Han, Clément François, Mondher Toumi
medRxiv 2020.06.22.20135434; doi: https://doi.org/10.1101/2020.06.22.20135434
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (679)
- Anesthesia (182)
- Cardiovascular Medicine (2687)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12318)
- Forensic Medicine (10)
- Gastroenterology (771)
- Genetic and Genomic Medicine (4161)
- Geriatric Medicine (390)
- Health Economics (685)
- Health Informatics (2699)
- Health Policy (1010)
- Hematology (365)
- HIV/AIDS (861)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (446)
- Neurology (3935)
- Nursing (213)
- Nutrition (586)
- Oncology (2073)
- Ophthalmology (596)
- Orthopedics (243)
- Otolaryngology (308)
- Pain Medicine (253)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1131)
- Primary Care Research (462)
- Public and Global Health (6583)
- Radiology and Imaging (1424)
- Respiratory Medicine (877)
- Rheumatology (414)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (55)
- Transplantation (191)
- Urology (170)